Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
-
Ramanathan, R. K. (Mayo Clinic (USA))
;
Goldstein, D. (Prince of Wales Hospital (Australia)) ;
Korn, R. L. (Scottsdale Medical Imaging, Ltd (USA)) ;
Arena, F. P (NYU Langone Arena Oncology (USA)) ;
Moore, M. (Provencial Health Services Authority. BC Cancer Agency (Canada)) ;
Siena, S. (Università degli Studi di Millano. Niguarda Cancer Center (Italy)) ;
Teixeira, L. (Hôpital Saint-Antoine (Paris, França)) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Van Laethem, J.-L. (University Clinic of Brussels. Hôpital Erasme (Belgium)) ;
Liu, H. (Biostatistics and Research and Design. Celgene Corporation (USA)) ;
McGovern, D. (Biostatistics and Research and Design. Celgene Corporation (USA)) ;
Lu, B. (Biostatistics and Research and Design. Celgene Corporation (USA)) ;
Von Hoff, D. D. (Translational Genomics Research Institute) ;
Universitat Autònoma de Barcelona
visitante ::
identificación
Subscribirse to this discussion. You will then receive all new comments by email.
